Evidence map›Paper›PMID 29119317›Full record

ArticleMicrobial ecology2018

Prodigiosin, Violacein, and Volatile Organic Compounds Produced by Widespread Cutaneous Bacteria of Amphibians Can Inhibit Two Batrachochytrium Fungal Pathogens.

Douglas C Woodhams, Brandon C LaBumbard, Kelly L Barnhart, Matthew H Becker, Molly C Bletz, Laura A Escobar, Sandra V Flechas, Megan E Forman, Anthony A Iannetta, Maureen D Joyce and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Microbial ecology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 147 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Mitigation of chytridiomycosis onMicrobiology spectrum · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. International journal of systematic and evolutionary microbiology · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 4 countries.

Douglas C WoodhamsBiology Department, University of Massachusetts Boston, Boston, MA, 02125, USA. dwoodhams@gmail.com.
Brandon C LaBumbardBiology Department, University of Massachusetts Boston, Boston, MA, 02125, USA.
Kelly L BarnhartBiology Department, University of Massachusetts Boston, Boston, MA, 02125, USA.
Matthew H BeckerSmithsonian Conservation Biology Institute, National Zoological Park, Washington, DC, USA.
Molly C BletzBiology Department, University of Massachusetts Boston, Boston, MA, 02125, USA.
Laura A EscobarSchool of Sciences, Pontificia Universidad Javeriana, Bogotá, AA 56710, Colombia.
Sandra V FlechasDepartment of Biological Sciences, Universidad de los Andes, Bogotá, AA 4976, Colombia.
Megan E FormanDepartment of Chemistry, Villanova University, Villanova, PA, 19085, USA.
Anthony A IannettaDepartment of Chemistry, Villanova University, Villanova, PA, 19085, USA.
Maureen D JoyceDepartment of Chemistry, Villanova University, Villanova, PA, 19085, USA.
Falitiana RabemananjaraUniversity of Antananarivo, Antananarivo, Madagascar.
Brian GratwickeSmithsonian Conservation Biology Institute, National Zoological Park, Washington, DC, USA.
Miguel VencesZoological Institute, Technische Universität Braunschweig, 38106, Braunschweig, Germany.
Kevin P C MinbioleDepartment of Chemistry, Villanova University, Villanova, PA, 19085, USA. kevin.minbiole@villanova.edu.
University of Massachusetts Boston · USVillanova University · USLiberty University · USNational Zoological Park · USPontificia Universidad Javeriana · COTechnische Universität Braunschweig · DEUniversidad de Los Andes · COUniversity of Antananarivo · MGUniversity of North Carolina at Chapel Hill · US

Funding

Division of Environmental Biology DEB-1136662
6 · The paper itself

Abstract

Symbiotic bacteria can produce secondary metabolites and volatile compounds that contribute to amphibian skin defense. Some of these symbionts have been used as probiotics to treat or prevent the emerging disease chytridiomycosis. We examined 20 amphibian cutaneous bacteria for the production of prodigiosin or violacein, brightly colored defense compounds that pigment the bacteria and have characteristic spectroscopic properties making them readily detectable, and evaluated the antifungal activity of these compounds. We detected violacein from all six isolates of Janthinobacterium lividum on frogs from the USA, Switzerland, and on captive frogs originally from Panama. We detected prodigiosin from five isolates of Serratia plymuthica or S. marcescens, but not from four isolates of S. fonticola or S. liquefaciens. All J. lividum isolates produced violacein when visibly purple, while prodigiosin was only detected on visibly red Serratia isolates. When applied to cultures of chytrid fungi Batrachochytrium dendrobatidis (Bd) and B. salamandrivorans (Bsal), prodigiosin caused significant growth inhibition, with minimal inhibitory concentrations (MIC) of 10 and 50 μM, respectively. Violacein showed a MIC of 15 μM against both fungi and was slightly more active against Bsal than Bd at lower concentrations. Although neither violacein nor prodigiosin showed aerosol activity and is not considered a volatile organic compound (VOC), J. lividum and several Serratia isolates did produce antifungal VOCs. White Serratia isolates with undetectable prodigiosin levels could still inhibit Bd growth indicating additional antifungal compounds in their chemical arsenals. Similarly, J. lividum can produce antifungal compounds such as indole-3-carboxaldehyde in addition to violacein, and isolates are not always purple, or turn purple under certain growth conditions. When Serratia isolates were grown in the presence of cell-free supernatant (CFS) from the fungi, CFS from Bd inhibited growth of the prodigiosin-producing isolates, perhaps indicative of an evolutionary arms race; Bsal CFS did not inhibit bacterial growth. In contrast, growth of one J. lividum isolate was facilitated by CFS from both fungi. Isolates that grow and continue to produce antifungal compounds in the presence of pathogens may represent promising probiotics for amphibians infected or at risk of chytridiomycosis. In a global analysis, 89% of tested Serratia isolates and 82% of J. lividum isolates were capable of inhibiting Bd and these have been reported from anurans and caudates from five continents, indicating their widespread distribution and potential for host benefit.

Indexed as

AnimalsAntifungal AgentsAnuraBacteriaBiological Control AgentsChytridiomycotaIndolesMicrobial Sensitivity TestsPanamaPhylogenyProdigiosinSerratiaSkinSwitzerlandSymbiosisUnited StatesAntifungal AgentsBiological Control Agentsindole-3-carbaldehydeIndolesProdigiosinviolaceinVolatile Organic CompoundsAmphibianAntifungalChytridiomycosisDisease ecologySecondary metabolitesSkin microbiota

Identifiers

PMID29119317
OpenAlexW2767998357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.